Retina

Patients treated for diabetic macular oedema with ranibizumab in the UK National Health Service (NHS) are getting benefits similar to those seen in clinical trials, according to a new study

Screening programmes could catch diabetic retinopathy in children earlier if they began screening 6 years after diabetes is diagnosed.

Studies in mice suggest that a technology based on topical endoscope fundus imaging could allow early diagnosis of Alzheimer’s disease, researchers have said.

Surgeons may safely delay operating on rhegmatogenous retinal detachment (RRD) for a few days to accommodate their schedules, a new study suggested.

The Novel Evidenced Assessment of Tortuosity (NEAT) system is intuitive and works even with poor images, according to its creators, Konstantinos Balaskas and his colleagues at Manchester Royal Eye Hospital and five other centres in the United Kingdom.

In a 1-year comparison of intravitreous aflibercept, bevacizumab and ranibizumab therapy for centre-involved DME, aflibercept was more effective at improving vision among patients who started treatment at lower levels of visual acuity.

Researchers using the AREDS lens grading scale have found that long-term clinically relevant outcomes can be predicted by 2-year changes in severity of lens opacities.

NICE has released a draft decision recognizing the benefits of aflibercept solution for injection for the majority of patients with visual impairment caused by DME.

Patients who receive triamcinolone acetonide treatment for DME demonstrate changes in OCT reflectivity in their foveal cystoid spaces that are associated with a rebound in macular thickening and visual deterioration.

The posterior retina is a site of oxytocin (OXT) activation of the oxytocin receptor (OXTR), according to a study published online.

The NHS is facing issues related to the diagnosing, treating and managing the growing number of ageing people affected by AMD, the leading cause of blindness in the Western world.

A proprietary retinal laser technology has demonstrated the potential to reverse the accumulation of drusen in patients with high-risk early AMD over a 24-month period.

Patients with polypoidal choroidal vasculopathy may benefit from intravitreal aflibercept.

Extensive pars plana vitrectomy and cataract extraction can significantly improve visual acuity in juvenile idiopathic arthritis patients suffering from severe ocular complications of uveitis.

Patients with diabetic macular oedema (DME) who received aflibercept injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to those who received either bevacizumab or ranibizumab.

There is a correlation between functional cell loss in the retina and signs of dementia in people who have a genetic risk for frontotemporal dementia (FTD), according to researchers from the US.

The US Food and Drug Administration (FDA) has approved a low-dose corticosteroid intravitreal implant for the treatment of diabetic macular oedema. (DME).

Monthly monitoring is no longer required for patients taking ranibizumab (Lucentis, Novartis) for a condition that is stable, due to a change in the drug's licence.

Non-damaging photothermal therapy using a pattern-scanning laser (PASCAL) guided by proprietary software is a safe and effective treatment for chronic central serous retinopathy (CSR), according to a recent study.

Long-term observational data presented at the 2014 European Society of Retina Specialists (EURETINA) conference support the safety and efficacy profile of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab (Lucentis, Novartis) for the treatment of appropriate patients across its indications

The European Commission has extended marketing authorization for an intravitreal implant with 700 mcg of dexamethasone in an applicator (Ozurdex, Allergan) for the treatment of adults with visual impairment caused by diabetic macular oedema (DME) who have pseudophakia or whose condition is considered insufficiently responsive to or unsuitable for non-corticosteroid therapy.

In a recent satellite symposium, sponsored by Bayer, the topic of macular oedema following CRVO was discussed by a panel of experts. Here, we present a summary of this meeting, highlighting the key outcomes.

KalVista Pharmaceuticals has begun a Phase I trial of its plasma kallikrein inhibitor KVD001 for the treatment of diabetic macular oedema (DME).

Researchers examining age-related changes in heparan sulphate (HS) quantity and composition in human Bruch's membrane (BrM) have discovered that the quantity greatly decreases with age, resulting in fewer binding sites for complement factor H (CFH) and affecting the ability of the 402H variant of CFH to bind BrM.

Aflibercept is effective in inhibiting vascular endothelial growth factor (VEGF) for a prolonged period of time, but possible side effects draw concerns about its long-term use in patients with age-related macular degeneration, diabetic macular oedema and retinal vein occlusion, according to the conclusions of a new study.